China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

Modified Rodnan Skin Score is the primary endpoint of the TibuSURE trial. Credit: Cesare Andrea Ferrari/Shutterstock. Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the ...

The company considers the T cell activator to have potential as a treatment option for high tumour mutation burden (TMB-H) cancers or virally associated malignancies. Credit: Meletios Verras / ...

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

Figure 1: Artificial intelligence clinical trials, 2020–2025. Source: GlobalData, Pharma Intelligence Center (Accessed: December 2024). © GlobalData. *To date F ...

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

Described as an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyktu saw sales of $170m in 2023 according to GlobalData. Credit: Shutterstock / Pormezz Bristol Myers Squibb (BMS) ...